Idorsia

Idorsia says it is on track to meet its targets after the first half of 2026 and maintains its full-year outlook. Total revenue fell to CHF 110 million, of which Quviviq accounted for CHF 91 million, up 62% year‑on‑year. On an operational US‑GAAP basis the company reported an operating loss of CHF 63 million and a net loss of CHF 152 million; higher finance expenses weighed on results. Cash and cash equivalents amounted to CHF 89 million at the end of June. For 2026 Idorsia expects Quviviq sales of around CHF 200 million and an operational US‑GAAP loss of about CHF 160 million. The company also reports progress with Aprocitentan and other pipeline projects and is negotiating distribution and co‑promotion partnerships. » Więcej na finanzen.net

Idorsia has entered into an exclusive agreement with Jamjoom Pharma for the approval, marketing and distribution of the sleep medication Quviviq in Saudi Arabia and the Levant. Jamjoom Pharma will manage regulatory approval and commercialization, while Idorsia will supply the finished product. Idorsia will receive an upfront payment and potential additional payments. » Więcej na finanzen.net

Idorsia has completed the announced credit agreement with Pharmakon Advisors. At the same time, the existing loan was repaid in full. » Więcej na finanzen.net